Potent and highly selective dual-targeting monoamine oxidase-B inhibitors: Fluorinated chalcones of morpholine versus imidazole.
Bijo MathewSeung C BaekDella G Thomas ParambiJae P LeeGitha E MathewSivaraman JayanthiDevaraji VinodClariya RaphealVinod DevikrishnaShahin Shad KondarathMd Sahab UddinHoon KimPublished in: Archiv der Pharmazie (2019)
Two series of fluorinated chalcones containing morpholine and imidazole-based compounds (f1-f8) were synthesized and evaluated for recombinant human monoamine oxidase (MAO)-A and -B as well as acetylcholinesterase inhibitory activities. Our results indicate that morpholine containing chalcones are highly selective MAO-B inhibitors having reversibility properties. All the imidazole-based fluorinated chalcones showed weak MAO inhibitions in both isoforms. Among the tested compounds, (2E)-3-(3-fluorophenyl)-1-[4-(morpholin-4-yl)phenyl]prop-2-en-1-one (f2) showed potent inhibitory activity for recombinant human MAO-B (IC50 = 0.087 μM) with a high selectivity index (SI) of 517.2. In the recovery experiments using dialysis, the residual activity of MAO-B inhibited by f2 was close to that with the reversible reference inhibitor. Inhibition assays revealed that the Ki values of f1 and f2 for MAO-B were 0.027 and 0.020 μM, respectively, with competitive patterns. All the morpholine-based compounds (f1-f4) showed moderate inhibition toward acetylcholinesterase with IC50 values ranging between 24 and 54 μM. All morpholine-containing compounds exhibit good blood-brain barrier permeation in the PAMPA method. The rational approach regarding the highly selective MAO-B inhibitor f2 was further ascertained by induced fit docking and molecular dynamics simulation studies.
Keyphrases
- recombinant human
- blood brain barrier
- molecular dynamics simulations
- chronic kidney disease
- squamous cell carcinoma
- molecular dynamics
- anti inflammatory
- high intensity
- molecular docking
- single cell
- high throughput
- high glucose
- radiation therapy
- oxidative stress
- endothelial cells
- brain injury
- room temperature
- rectal cancer
- neoadjuvant chemotherapy